Project Grant R01HL179702
Award Date 9/1/25
Completion Date 6/30/30
Dollars Obligated $732K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94158, USA
Similar Awards
- The federal Project Grant award R56AG088161 was provided by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) to support research into the use of hypoxia (low oxygen) therapy to treat mitochondrial diseases. The $472,500 award, with a period of performance from September 2024 to August 2025, will enable the J. David Gladstone Institutes, a non-profit biomedical research organization in San Francisco, to investigate the mechanisms by which hypoxia can rescue...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $811,885 in funding to the J. David Gladstone Institutes in California to conduct research on epigenomic mechanisms of cardiac fibrosis and heart failure. The project aims to investigate the role of the MEOX1 gene as a key transcriptional regulator of fibroblast activation, fibrosis, and heart failure pathogenesis. The research leverages novel genetic mouse...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $166,395 to Columbia University to conduct a 5-year research project on the impact of hyperoxia (excess oxygen) on the function of respiratory progenitor cells in neonates. The project aims to develop a better understanding of the mechanisms by which post-natal lung development occurs in the face of injurious agents like oxygen...
- The National Heart, Lung, and Blood Institute (NHLBI), via the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $564,445 Project Grant to the University of Texas Health Science Center at Houston (UTHealth) to fund research on "Targeting Hypoxia-Inducible Factors (HIFs) for Heart and Lung Disease." The 6-year grant, starting on March 1, 2025 and ending on December 31, 2031, supports three complementary research projects focused on investigating the upstream regulation...
- The federal Project Grant award of $678,803.00 was provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) to The Ohio State University. The funding supports research to investigate the role of the mitochondrial deubiquitinase USP30 in regulating microvascular endothelial cell function and its potential as a therapeutic target for acute inflammatory diseases like acute respiratory distress syndrome (ARDS) and sepsis. Key...
- The U.S. National Heart, Lung, and Blood Institute awarded a $803,768 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the J. David Gladstone Institutes, a non-profit biomedical research organization in California. The grant funding supports a research project titled "Chromatin Regulation of Immune Cells in Myocardial Inflammation", which aims to elucidate the role of the epigenetic regulator BRD4 in controlling monocyte differentiation and macrophage...
- This federal Project Grant award, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the role of purinergic signaling in fibroblast activation and lung fibrosis. The $728,577 grant, awarded to the Regents of the University of California, San Francisco, aims to investigate the mechanisms by which the ATP receptor P2RX4 influences fibrotic pathways in lung fibroblasts. The research seeks to elucidate the...
- This federal Project Grant award of $552,318 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to investigate the role of carbonic anhydrase as a cardioprotective target for mitigating the cardiotoxic effects of anthracycline chemotherapy drugs like doxorubicin. The research leverages human-induced pluripotent stem cell-derived cardiomyocytes to model anthracycline-induced cardiotoxicity and uses CRISPR interference/activation...
- This Project Grant award of $576,786.00, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research at the University of Arizona to investigate the role of the YTHD2 protein in regulating the translation of the NRF2 protein under conditions of oxidative stress. The research aims to elucidate the mechanisms by which certain proteins, like NRF2, can continue to be translated despite the general inhibition of protein...
- The federal Project Grant award of $420,000 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) supports research to identify the molecular mechanisms of mitochondrial dysfunction in pathological stress conditions. The primary objective is to investigate the processes of oxidative phosphorylation and mitochondrial membrane potential disruption, which can lead to cell death and tissue damage in various diseases....